Yun Dai

ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 22

Top Venues

Annals of hematology

American journal of hematology

Journal of hematology & oncology

Blood

Jilin University

Virginia Commonwealth University (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Jilin University Oct 21 2015

China

Professor :: The First Hospital

Virginia Commonwealth University Jul 01 2010

United States

Associate Professor :: Medicine, Massey cancer Center

Education History

Virginia Commonwealth University May 08 2012 - Aug 15 2015

United States

MSC :: Center for Clinical and Translational Research

Southern Medical University Sep 01 1991 - Jul 16 1994

China

PHD :: Cell Biology

Publications

Yingjie Zhang, Xinyue Liang, Weiling Xu, Xingcheng Yi, Rui Hu, Xintian Ma, Yurong Yan, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Yufeng Zhu, Mengru Tian, Maozhuo Lan, Mengtuan Long, Yun Dai, Fengyan Jin
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study. Journal of hematology & oncology 17 (1) (2024)
Yingjie Zhang, Xinyue Liang, Weiling Xu, Xingcheng Yi, Rui Hu, Xintian Ma, Yurong Yan, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Yufeng Zhu, Mengru Tian, Maozhuo Lan, Mengtuan Long, Yun Dai, Fengyan Jin
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study. Journal of hematology & oncology 17 (1) (2024)
Yingjie Zhang, Xinyue Liang, Weiling Xu, Xingcheng Yi, Rui Hu, Xintian Ma, Yurong Yan, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Yufeng Zhu, Mengru Tian, Maozhuo Lan, Mengtuan Long, Yun Dai, Fengyan Jin
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study. Journal of hematology & oncology 17 (1) (2024)
Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Xiaoxia Zhao, Yun Dai, Fengyan Jin
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma. Annals of hematology (2023)
Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Xiaoxia Zhao, Yun Dai, Fengyan Jin
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma. Annals of hematology 102 (4) (2023)
Mengru Tian, Xinyue Liang, Weiling Xu, Xingcheng Yi, Tingting Yue, Yingjie Zhang, Shanshan Yu, Yurong Yan, Zhongli Hu, Nan Zhang, Jingxuan Wang, Rui Hu, Xiaoxiao Sun, Yuanyuan Nie, Yun Dai, Fengyan Jin
More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma. Annals of hematology (2023)
Shulan Han, Xueying Bao, Yifang Zou, Lingzhi Wang, Yutong Li, Leilei Yang, Anqi Liao, Xuemei Zhang, Xin Jiang, Di Liang, Yun Dai, Qing-Chuan Zheng, Zhuo Yu, Jianfeng Guo
d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Science advances 9 (29) (2023)
Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Xiaoxia Zhao, Yun Dai, Fengyan Jin
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma. Annals of hematology 102 (4) (2023)
Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Xiaoxia Zhao, Yun Dai, Fengyan Jin
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma. Annals of hematology (2023)
Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Xiaoxia Zhao, Yun Dai, Fengyan Jin
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma. Annals of hematology 102 (4) (2023)
Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Xiaoxia Zhao, Yun Dai, Fengyan Jin
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma. Annals of hematology 102 (4) (2023)
Peiyu Yang, Fan Zhou, Yujun Dong, Guangxun Gao, Hua Xue, Xinyue Liang, Shanshan Yu, Weiling Xu, Yanping Ma, Xiaoqi Qin, Mengyao Li, Yun Dai, Fengyan Jin
The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma. Blood cancer journal 12 (9) (2022)
Peiyu Yang, Weiling Xu, Xinyue Liang, Shanshan Yu, Xingcheng Yi, Mengmeng Liu, Mengru Tian, Tingting Yue, Yingjie Zhang, Yurong Yan, Zhongli Hu, Qiang Guo, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Rui Hu, Shaji K Kumar, Yun Dai, Fengyan Jin
Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma. American journal of hematology 98 (3) (2022)
Peiyu Yang, Weiling Xu, Xinyue Liang, Shanshan Yu, Xingcheng Yi, Mengmeng Liu, Mengru Tian, Tingting Yue, Yingjie Zhang, Yurong Yan, Zhongli Hu, Qiang Guo, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Rui Hu, Shaji K Kumar, Yun Dai, Fengyan Jin
Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma. American journal of hematology (2022)
Peiyu Yang, Weiling Xu, Xinyue Liang, Shanshan Yu, Xingcheng Yi, Mengmeng Liu, Mengru Tian, Tingting Yue, Yingjie Zhang, Yurong Yan, Zhongli Hu, Qiang Guo, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Rui Hu, Shaji K Kumar, Yun Dai, Fengyan Jin
Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma. American journal of hematology 98 (3) (2022)
Peiyu Yang, Haimin Chen, Xinyue Liang, Weiling Xu, Shanshan Yu, Wenyang Huang, Xingcheng Yi, Qiang Guo, Mengru Tian, Tingting Yue, Mengyao Li, Yingjie Zhang, Mengxue Zhang, Yurong Yan, Zhongli Hu, Shaji K Kumar, Fan Zhou, Yun Dai, Fengyan Jin
Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma. American journal of hematology (2022)
Peiyu Yang, Weiling Xu, Xinyue Liang, Shanshan Yu, Xingcheng Yi, Mengmeng Liu, Mengru Tian, Tingting Yue, Yingjie Zhang, Yurong Yan, Zhongli Hu, Qiang Guo, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Rui Hu, Shaji K Kumar, Yun Dai, Fengyan Jin
Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma. American journal of hematology 98 (3) (2022)
Peiyu Yang, Weiling Xu, Xinyue Liang, Shanshan Yu, Xingcheng Yi, Mengmeng Liu, Mengru Tian, Tingting Yue, Yingjie Zhang, Yurong Yan, Zhongli Hu, Qiang Guo, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Rui Hu, Shaji K Kumar, Yun Dai, Fengyan Jin
Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma. American journal of hematology 98 (3) (2022)
Fengyan Jin, Jian Li, Jianfeng Guo, Thorsten R Doeppner, Dirk M Hermann, Gang Yao, Yun Dai
Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. European heart journal open 1 (2) (2021)
Fengyan Jin, Nina Hagemann, Li Sun, Jiang Wu, Thorsten R Doeppner, Yun Dai, Dirk M Hermann
High-density lipoprotein (HDL) promotes angiogenesis via S1P3-dependent VEGFR2 activation. Angiogenesis 21 (2) (2018)
Chuan Wu, Ting Yang, Yingmin Liu, Yicheng Lu, Yanping Yang, Xiaobo Liu, Xuelian Liu, Long Ye, Yue Sun, Xue Wang, Qingchao Li, Peiyu Yang, Xiaoyuan Yu, Sujun Gao, Shaji Kumar, Fengyan Jin, Yun Dai, Wei Li
ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Cancer medicine 7 (8) (2018)
Liang Zhou, Shuang Chen, Yu Zhang, Maciej Kmieciak, Yun Leng, Lihong Li, Hui Lin, Kathryn A Rizzo, Catherine I Dumur, Andrea Ferreira-Gonzalez, Mohamed Rahmani, Lawrence Povirk, Sri Chalasani, Allison J Berger, Yun Dai, Steven Grant
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood 127 (18) (2016)
Shuang Chen, Yu Zhang, Liang Zhou, Yun Leng, Hui Lin, Maciej Kmieciak, Xin-Yan Pei, Richard Jones, Robert Z Orlowski, Yun Dai, Steven Grant
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124 (17) (2014)

Yun Dai.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yun Dai